CD19
Assets acting on this target.
- Class
- CD19-directed (binds CD19 on B cells)
- Pathway
- Engineered NK cells recognize and eliminate CD19-expressing B cells implicated in autoimmune disease
CD19 is a transmembrane glycoprotein expressed across almost the entire B-lymphocyte lineage, from early progenitor cells through mature B cells, though it is largely absent from terminally differentiated plasma cells. Because B cells are central to antibody-mediated autoimmune disease (producing pathogenic autoantibodies, presenting antigens to T cells, and secreting inflammatory cytokines), eliminating CD19-expressing cells offers a way to interrupt these pathogenic circuits. Chimeric antigen receptor (CAR) technology can redirect immune effector cells to recognize CD19 and destroy the cells bearing it. This targeting logic, first developed for cancer using a patient's own T cells, can also be applied to autoimmune disease and paired with natural killer (NK) cells, cytotoxic lymphocytes that mediate rapid target-cell killing without requiring prior antigen sensitization. Using allogeneic NK cells sourced from healthy donors rather than autologous T cells allows for 'off-the-shelf' manufacturing, avoiding the delays associated with individualized cell collection and engineering. This mechanism broadly matters wherever pathogenic B cells sustain autoimmune disease, including conditions in which conventional immunosuppression or antibody-based B cell depletion has proven inadequate.
By indication
Related mechanisms
CD19 drugs compared
17 drugs, stage by indication
| Drug | Developer | Modality | Furthest stage | Stage by indication |
|---|---|---|---|---|
| Inebilizumab | Amgen, Hansoh Pharmaceutical Group, Tanabe Pharma Corporation | monoclonal antibody | Approved | Approved in Generalized Myasthenia Gravis; Phase 2 in Systemic Lupus Erythematosus |
| obecabtagene autoleucelAucatzyl | Autolus Therapeutics plc | CAR-T cell therapy | Approved | Approved in Acute Lymphoblastic Leukemia |
| Tafasitamab | Beijing InnoCare Pharma Tech Co., Incyte, Xencor | monoclonal antibody | Approved | Approved in Diffuse Large B-Cell Lymphoma; Approved in Follicular Lymphoma; Approved in Large B-Cell Lymphoma |
| budoprutug | Climb Bio, Inc. | monoclonal antibody | Phase 2 | Phase 2 in Primary Membranous Nephropathy; Phase 1/2 in Systemic Lupus Erythematosus |
| cemacabtagene ansegedleucel | Allogene Therapeutics, Inc. | cell therapy | Phase 2 | Phase 2 in Large B-Cell Lymphoma |
| FT819 | Fate Therapeutics | CAR-T cell therapy | Phase 2 | Phase 2 in Systemic Lupus Erythematosus |
| Rapcabtagene autoleucel | Novartis | undisclosed | Phase 2 | Phase 2 in Lupus Nephritis |
| Beijing Biotech anti-CD19 CAR-T | Beijing Biotech | CAR-T cell therapy | Phase 1/2 | Phase 1/2 in Systemic Lupus Erythematosus |
| Zugocabtagene geleucel | CRISPR Therapeutics | CAR-T | Phase 1/2 | Phase 1/2 in Follicular Lymphoma; Phase 1 in Systemic Lupus Erythematosus |
| ABBV-319 | AbbVie | antibody-drug conjugate | Phase 1 | Phase 1 in Rheumatoid Arthritis; Phase 1 in Sjögren's Disease; Phase 1 in Systemic Lupus Erythematosus |
| ABBV-519 | AbbVie | Not recorded | Phase 1 | Phase 1 in Rheumatoid Arthritis; Phase 1 in Systemic Lupus Erythematosus |
| Azercabtagene zapreleucel | Imugene Limited, PRECISION BIOSCIENCES INC, TG THERAPEUTICS, INC. | cell therapy | Phase 1 | Not recorded |
| IC19 CAR-T | Beijing Immunochina Medical Science & Technology Co., Ltd. | CAR-T cell therapy | Phase 1 | Phase 1 in Systemic Lupus Erythematosus |
| UTAA09 | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | CAR-T cell therapy | Phase 1 | Phase 1 in Systemic Lupus Erythematosus |
| ZM001 | Beijing Immunochina Medical Science & Technology Co., Ltd. | CAR-T | Phase 1 | Phase 1 in Systemic Lupus Erythematosus |
| ABBV-619 | AbbVie | undisclosed | Stage not recorded | Not recorded |
| FT522 | Fate Therapeutics | cell therapy | Stage not recorded | Not recorded |